Teva Pharmaceuticals USA, Inc 2026-04-01 Health serious FDA
Health · FDA · Recall #FDA-D-0404-2026
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg,… Recall
Issued April 1, 2026 · Teva Pharmaceuticals USA, Inc
In April 2026, Teva Pharmaceuticals USA, Inc recalled the Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg,…, a serious health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
What you should do
- 1 Stop using Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg,… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Teva Pharmaceuticals USA, Inc to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Teva Pharmaceuticals USA, Inc
- Category
- Health
- Recall date
- April 1, 2026
- Units affected
- Not reported
- Sold at
- Nationwide in the USA
- Recall number
- FDA-D-0404-2026
- Made in
- United States
- Issuing agency
- FDA
In context
- Teva Pharmaceuticals USA, Inc has 13 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 356th Health recall we've logged in 2026.